We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Global Point of Care Diagnostics Market Expected to Reach USD 71 Billion in 2027

By LabMedica International staff writers
Posted on 22 Aug 2021
Print article
Illustration
Illustration
The global point of care diagnostics market is estimated to register a CAGR of 11.8% from 2019-2027 and grow from USD 26.60 billion in 2018 to USD 70.89 billion in 2027, driven by the introduction of new point-of-care testing (POCT) products that are aimed at delivering inexpensive care at facilities located at the closest-possible distances from the patients’ location.

These are the latest findings of a market research study by The Insight Partners (Pune, India), a market research & consulting firm.

POCT plays a critical role in the diagnosis, treatment, and prevention of infectious diseases. POC testing can be used to detect several major pathogens, including malarial parasites; human immunodeficiency virus (HIV); human papillomavirus (HPV); dengue, Ebola, and Zika viruses; and Mycobacterium tuberculosis (TB bacteria). To narrow down the diagnostic time, companies are developing POC test kits and reagents. The number of POCT has steadily increased over the last 40 years since its widespread introduction. The market growth is likely to continue with the help of the introduction of new products in the market aimed at delivering inexpensive care at the facilities located at the closest-possible distances from the patients’ location. New technologies or products are being refined and improved to deliver easier-to-use devices with incremental improvements in analytical performance.

Based on product, the global point of care diagnostics market was led by the glucose monitoring products segment in 2018 with the largest share. This segment is also expected to dominate the market until 2027 owing to the increase in the number of diabetic patients. However, the infectious disease testing products market is expected to grow at a significant rate during the forecast period. Moreover, infectious disease rapid test kits are widely available for a wide variety of prophlogistic pathogen targets, including bacterial, viral, fungal, protozoan, and other disease agents.

The global point of care diagnostics market has witnessed various organic as well as inorganic developments during recent years, including growth strategies such as approvals, collaborations, and partnerships. Geographically, Asia Pacific is the fastest growing point of care diagnostics market and is expected to be a significant revenue contributor during the forecast period. The region has witnessed several technological advancements in the field of healthcare with the incorporation of point of care diagnostics for increasing the efficiency of treatments. Additionally, there is growing interest among international players in China and India, government support in countries such as China, and improving healthcare infrastructure. Hence, players in the Asia Pacific point of care diagnostics market have huge potential for growth during the forecast period.

Related Links:
The Insight Partners

Gold Supplier
Chromogenic Medium
CHROMagar Candida Plus
New
3-Part Diff Hematology Analyzer
DLB3
New
Gold Supplier
Chemistry Analyzer
BS-600M
New
Automated Nucleic Acid Extraction System
NuActor

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.